Clinical Oncology

Staff

Chief Yusuke Onozawa, M.D.

Features of Clinical Oncology

In general, a cancer originates in some organ, and spreads to other organs as it progresses. Even when it metastasizes, it is considered that it takes on the characteristics of the primary tumor and the treatment method will be tailored in accordance with it. However, there is a case sometimes that only the metastasized tumor is detected at the time of diagnosis, and even with various examinations, the primary tumor may remain unknown. In a case as such, it is called “cancer of unknown primary” and the Division of Clinical Oncology will be responsible for the treatment of that type of cancer.

Features and Therapeutic Strategies of the Division at the SCC

Various tests and examinations will lead to identification of primary tumor.

Cancer of unknown primary is brought to pathological tests and diagnostic imaging in search for where it has originated or in presuming it. Experienced medical staff including pathologists often leads to the identification of the primary lesion.

Optimal treatment is provided in collaboration with many clinical departments even when the primary lesion remains unknown.

Even with various tests and examinations, primary lesion might remain unknown sometimes. The case will be handled as “a cancer with unknown primary,” and we provide the treatment (mostly with anti-cancer drugs) at this division. The doctor having experienced many cases of unknown primaries will carefully examine how the patient’s general condition is before suggesting the best possible cancer treatment. In most cases, it will involve anti-cancer drugs, but there can be a case requiring a surgical treatment (operation).

A Word from the Division Staff

There have been more and more hospitals accepting cancers with unknown primaries in Shizuoka prefecture, but the number of those hospitals is still quite small. We hope to be able to contribute to cancer medicine in this region.

Fields of Expertise, Professional Memberships and Credentials

Yusuke Onozawa, M.D., Chief

Fields of Expertise

chemotherapy for gastroenterological cancer (i.e., gastrointestinal lymphoma, gastrointestinal stromal tumor (GIST)) and cancer in the head and neck region

Professional Memberships and Credentials

Interim Supervisory Doctor, Councilor, Certified Specialist and Supervisory Doctor for Cancer Chemotherapy, the Japanese Society of Medical Oncology

General Clinical Oncologist Certified by the Japanese Board of Cancer Therapy

Certified Physician, Specialist and Supervisory Doctor, the Japanese Society of Internal Medicine

Specialist Certified by the Japanese Society of Gastroenterology

The Japan Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO)
The Japanese Society of Hematology
The Japan Society for Head and Neck Cancer

The Japanese Society for Transplantation and Cellular Therapy

The Japan Society of Transfusion Medicine and Cell Therapy

The Japan Gastroenterological Endoscopy Society